Shanghai, China, 30 October 2021 - MicroPort CardioFlow Medtech Corp. ("CardioFlow Medtech") presented the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty™"), an independently developed next-generation product for transcatheter aortic valve Implantation ("TAVI"), and hosted a launch event for the product at China Structural Week 2021 and the 5th China International Structural Heart Disease Conference, which were simultaneously held in Beijing, Shanghai, Guangzhou, and Xi'an. The product drew the attention of experts in the field of structural heart disease and triggered discussions on the development of the TAVI procedure among the attending experts.

It is estimated that 25 million people are suffering from valvular heart disease in China at present. As China's population aging trend intensifies, an increasing number of patients will require TAVI treatment in the future. Over the past two years since its launch, CardioFlow Medtech's TAVI product VitaFlow® has become available in over 260 hospitals in China. Approved for marketing in August, the new-generation VitaFlow Liberty™ is the only motorized retrievable TAVI system commercially available in the world. Its innovative motorized handle allows for fast, stable and accurate release and retrieval, providing surgeons with better control over the procedure. In addition, it is also the only delivery system commercially available in the Chinese market that features a 360-degree bendable distal end, with superior flexibility that can effectively help minimize blood vessel damage. Meanwhile, VitaFlow Liberty™ inherits the hybrid density stent design of VitaFlow®, the first-generation TAVI product by CardioFlow Medtech, and continues to use bovine pericardium as its leaflet material for better durability. Its sensible double-layer skirts design helps effectively prevent perivalvular leakage to a larger extent.

During the conference, many experts and scholars in the field of structural heart disease witnessed the launch of VitaFlow Liberty™. They include Prof. Yuan Bai from the Changhai Hospital of Shanghai, Prof. Yuan Feng from the West China Hospital of Sichuan University, Prof. Lang Hong from the People's Hospital of Jiangxi Province, Prof. Yu Jiang from the First Affiliated Hospital of Nanchang University, Prof. Zhengming Jiang from the First Affiliated Hospital of Zhengzhou University, Prof. Jie Li from the People's Hospital of Guangdong Province, Prof. Ping Li from the Yulin First People's Hospital, Prof. Xianbao Liu from the Second Affiliated Hospital of Zhejiang University School of Medicine, Prof. Wei Liu from the Beijing Jishuitan Hospital, Prof. Jianfang Luo from the People's Hospital of Guangdong Province, Prof. Guangyuan Song from Beijing Anzhen Hospital of Capital Medical University, Prof. Yongjian Wu from the Fuwai Hospital of Chinese Academy of Medical Sciences, Prof. Zhengbin Zhu from the Ruijin Hospital, affiliated to Shanghai Jiaotong University School of Medicine.

The superior user experience of the motorized retrievable system of VitaFlow Liberty™ triggered a lively discussion among the experts. Prof. Yongjian Wu commented, "For most surgeons, the changes brought by the VitaFlow Liberty™ Retrievable System is not limited to intraoperative operation, but it also improves the mindset of the operator. First of all, it liberates the surgeon and stabilizes blood pressure, while it also enables better surgical results for patients."

Mr. Guoming Chen, President of CardioFlow Medtech, said, "CardioFlow Medtech has witnessed the development of TAVI China for ten years. It is predicted that the total number of TAVI performed in China will reach 8,000 for the first time this year. The launch of the new-generation VitaFlow Liberty™ heralds a new era of motorized retrievable TAVI systems in China. In addition, CardioFlow Medtech is also actively exploring the field of mitral and tricuspid valves diseases, and it will use its strength in innovation to ensure the core competitiveness of its future products and provide a total solution for valve diseases in general, with the aim of providing more convenience for the surgeons while ensuring a better prognosis for the patient."

Attachments

  • Original document
  • Permalink

Disclaimer

MicroPort Scientific Corporation published this content on 31 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2021 09:16:05 UTC.